Recombinant vaccines are produced using recombinant DNA technology, with the help of a vector. These vaccines stimulate the immune system of an individual and provide immunity against various lethal disease.

These vaccines are safe and have less or no side-effects as compared to conventional vaccines, in the prevention of various diseases such as influenza, cholera, typhoid, and dengue.

Recombinant vaccines are also used in animals for prevention of diseases such as foot and mouth disease, pneumonia and septicemia, and pox disease. Vaccination results in the prevention of disease, by producing antibodies against the protein antigen of pathogenic microorganisms.

The market is mainly driven by the significant applications of Recombinant Vaccines in various end use industries. The expanding demands from the Recombinant Human Vaccines and Animal Recombinant Vaccines, are propelling Recombinant Vaccines market. Subunit Recombinant Vaccines, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Attenuated Recombinant Vaccines segment is estimated at % CAGR for the next seven-year period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Objectives

This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Recombinant Vaccines, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:

This report provides in-depth analysis of the global Recombinant Vaccines market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.

This report profiles key players in the global Recombinant Vaccines market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Recombinant Vaccines sales data, market share and ranking.

This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.

This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.

Key companies of Recombinant Vaccines covered in this report include Merck & Co., Inc, Green Cross Corporation, Pfizer Inc., Bayer AG, Sanofi S A., Protein Science Corporation, GlaxoSmithKline Plc., Novartis AG and Bharat Biotech, etc.

The global Recombinant Vaccines market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.

Market Segmentation

Company Profiles:

Merck & Co., Inc

Green Cross Corporation

Pfizer Inc.

Bayer AG

Sanofi S A.

Protein Science Corporation

GlaxoSmithKline Plc.

Novartis AG

Bharat Biotech

AstraZeneca Plc.

Johnson & Johnson

Emergent BioSolutions Inc

Novavax, Inc

Serum Institute of India Pvt. Ltd

Dynavax Technologies Corporation

Scope of Recombinant Vaccines - Market Report

Report Metric	Details
Report Name	Recombinant Vaccines - Market
Forecasted market size in 2029	US$ 17170 million
CAGR	11.0%
Forecasted years	2023 - 2029
Global Recombinant Vaccines market, by region:	North America (U.S., Canada, Mexico) Europe (Germany, France, UK, Italy, etc.) Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.) South America (Brazil, etc.) Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Recombinant Vaccines market, Segment by Type:	Subunit Recombinant Vaccines Attenuated Recombinant Vaccines Vector Recombinant Vaccines
Global Recombinant Vaccines market, by Application	Recombinant Human Vaccines Animal Recombinant Vaccines
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Recombinant Vaccines companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion

FAQ for this report

What is the Recombinant Vaccines - Market size in 2029?

Ans: The Recombinant Vaccines - Market size in 2029 will be US$ 17170 million.

What are the Application segmentation covered in the Recombinant Vaccines - Market report?

Ans: The Applications covered in the Recombinant Vaccines - Market report are Recombinant Human Vaccines, Animal Recombinant Vaccines

What are the Type segmentation covered in the Recombinant Vaccines - Market report?

Ans: The Types covered in the Recombinant Vaccines - Market report are Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines, Vector Recombinant Vaccines

1 Market Overview of Recombinant Vaccines

1.1 Recombinant Vaccines Market Overview

1.1.1 Recombinant Vaccines Product Scope

1.1.2 Recombinant Vaccines Market Status and Outlook

1.2 Global Recombinant Vaccines Market Size Overview by Region 2018 VS 2022 VS 2029

1.3 Global Recombinant Vaccines Market Size by Region (2018-2029)

1.4 Global Recombinant Vaccines Historic Market Size by Region (2018-2023)

1.5 Global Recombinant Vaccines Market Size Forecast by Region (2024-2029)

1.6 Key Regions, Recombinant Vaccines Market Size (2018-2029)

1.6.1 North America Recombinant Vaccines Market Size (2018-2029)

1.6.2 Europe Recombinant Vaccines Market Size (2018-2029)

1.6.3 Asia-Pacific Recombinant Vaccines Market Size (2018-2029)

1.6.4 Latin America Recombinant Vaccines Market Size (2018-2029)

1.6.5 Middle East & Africa Recombinant Vaccines Market Size (2018-2029)

2 Recombinant Vaccines Market by Type

2.1 Introduction

2.1.1 Subunit Recombinant Vaccines

2.1.2 Attenuated Recombinant Vaccines

2.1.3 Vector Recombinant Vaccines

2.2 Global Recombinant Vaccines Market Size by Type: 2018 VS 2022 VS 2029

2.2.1 Global Recombinant Vaccines Historic Market Size by Type (2018-2023)

2.2.2 Global Recombinant Vaccines Forecasted Market Size by Type (2024-2029)

2.3 Key Regions Market Size by Type

2.3.1 North America Recombinant Vaccines Revenue Breakdown by Type (2018-2029)

2.3.2 Europe Recombinant Vaccines Revenue Breakdown by Type (2018-2029)

2.3.3 Asia-Pacific Recombinant Vaccines Revenue Breakdown by Type (2018-2029)

2.3.4 Latin America Recombinant Vaccines Revenue Breakdown by Type (2018-2029)

2.3.5 Middle East and Africa Recombinant Vaccines Revenue Breakdown by Type (2018-2029)

3 Recombinant Vaccines Market Overview by Application

3.1 Introduction

3.1.1 Recombinant Human Vaccines

3.1.2 Animal Recombinant Vaccines

3.2 Global Recombinant Vaccines Market Size by Application: 2018 VS 2022 VS 2029

3.2.1 Global Recombinant Vaccines Historic Market Size by Application (2018-2023)

3.2.2 Global Recombinant Vaccines Forecasted Market Size by Application (2024-2029)

3.3 Key Regions Market Size by Application

3.3.1 North America Recombinant Vaccines Revenue Breakdown by Application (2018-2029)

3.3.2 Europe Recombinant Vaccines Revenue Breakdown by Application (2018-2029)

3.3.3 Asia-Pacific Recombinant Vaccines Revenue Breakdown by Application (2018-2029)

3.3.4 Latin America Recombinant Vaccines Revenue Breakdown by Application (2018-2029)

3.3.5 Middle East and Africa Recombinant Vaccines Revenue Breakdown by Application (2018-2029)

4 Recombinant Vaccines Competition Analysis by Players

4.1 Global Recombinant Vaccines Market Size by Players (2018-2023)

4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Recombinant Vaccines as of 2022)

4.3 Date of Key Players Enter into Recombinant Vaccines Market

4.4 Global Top Players Recombinant Vaccines Headquarters and Area Served

4.5 Key Players Recombinant Vaccines Product Solution and Service

4.6 Competitive Status

4.6.1 Recombinant Vaccines Market Concentration Rate

4.6.2 Mergers & Acquisitions, Expansion Plans

5 Company (Top Players) Profiles

5.1 Merck & Co., Inc

5.1.1 Merck & Co., Inc Profile

5.1.2 Merck & Co., Inc Main Business

5.1.3 Merck & Co., Inc Recombinant Vaccines Products, Services and Solutions

5.1.4 Merck & Co., Inc Recombinant Vaccines Revenue (US$ Million) & (2018-2023)

5.1.5 Merck & Co., Inc Recent Developments

5.2 Green Cross Corporation

5.2.1 Green Cross Corporation Profile

5.2.2 Green Cross Corporation Main Business

5.2.3 Green Cross Corporation Recombinant Vaccines Products, Services and Solutions

5.2.4 Green Cross Corporation Recombinant Vaccines Revenue (US$ Million) & (2018-2023)

5.2.5 Green Cross Corporation Recent Developments

5.3 Pfizer Inc.

5.3.1 Pfizer Inc. Profile

5.3.2 Pfizer Inc. Main Business

5.3.3 Pfizer Inc. Recombinant Vaccines Products, Services and Solutions

5.3.4 Pfizer Inc. Recombinant Vaccines Revenue (US$ Million) & (2018-2023)

5.3.5 Bayer AG Recent Developments

5.4 Bayer AG

5.4.1 Bayer AG Profile

5.4.2 Bayer AG Main Business

5.4.3 Bayer AG Recombinant Vaccines Products, Services and Solutions

5.4.4 Bayer AG Recombinant Vaccines Revenue (US$ Million) & (2018-2023)

5.4.5 Bayer AG Recent Developments

5.5 Sanofi S A.

5.5.1 Sanofi S A. Profile

5.5.2 Sanofi S A. Main Business

5.5.3 Sanofi S A. Recombinant Vaccines Products, Services and Solutions

5.5.4 Sanofi S A. Recombinant Vaccines Revenue (US$ Million) & (2018-2023)

5.5.5 Sanofi S A. Recent Developments

5.6 Protein Science Corporation

5.6.1 Protein Science Corporation Profile

5.6.2 Protein Science Corporation Main Business

5.6.3 Protein Science Corporation Recombinant Vaccines Products, Services and Solutions

5.6.4 Protein Science Corporation Recombinant Vaccines Revenue (US$ Million) & (2018-2023)

5.6.5 Protein Science Corporation Recent Developments

5.7 GlaxoSmithKline Plc.

5.7.1 GlaxoSmithKline Plc. Profile

5.7.2 GlaxoSmithKline Plc. Main Business

5.7.3 GlaxoSmithKline Plc. Recombinant Vaccines Products, Services and Solutions

5.7.4 GlaxoSmithKline Plc. Recombinant Vaccines Revenue (US$ Million) & (2018-2023)

5.7.5 GlaxoSmithKline Plc. Recent Developments

5.8 Novartis AG

5.8.1 Novartis AG Profile

5.8.2 Novartis AG Main Business

5.8.3 Novartis AG Recombinant Vaccines Products, Services and Solutions

5.8.4 Novartis AG Recombinant Vaccines Revenue (US$ Million) & (2018-2023)

5.8.5 Novartis AG Recent Developments

5.9 Bharat Biotech

5.9.1 Bharat Biotech Profile

5.9.2 Bharat Biotech Main Business

5.9.3 Bharat Biotech Recombinant Vaccines Products, Services and Solutions

5.9.4 Bharat Biotech Recombinant Vaccines Revenue (US$ Million) & (2018-2023)

5.9.5 Bharat Biotech Recent Developments

5.10 AstraZeneca Plc.

5.10.1 AstraZeneca Plc. Profile

5.10.2 AstraZeneca Plc. Main Business

5.10.3 AstraZeneca Plc. Recombinant Vaccines Products, Services and Solutions

5.10.4 AstraZeneca Plc. Recombinant Vaccines Revenue (US$ Million) & (2018-2023)

5.10.5 AstraZeneca Plc. Recent Developments

5.11 Johnson & Johnson

5.11.1 Johnson & Johnson Profile

5.11.2 Johnson & Johnson Main Business

5.11.3 Johnson & Johnson Recombinant Vaccines Products, Services and Solutions

5.11.4 Johnson & Johnson Recombinant Vaccines Revenue (US$ Million) & (2018-2023)

5.11.5 Johnson & Johnson Recent Developments

5.12 Emergent BioSolutions Inc

5.12.1 Emergent BioSolutions Inc Profile

5.12.2 Emergent BioSolutions Inc Main Business

5.12.3 Emergent BioSolutions Inc Recombinant Vaccines Products, Services and Solutions

5.12.4 Emergent BioSolutions Inc Recombinant Vaccines Revenue (US$ Million) & (2018-2023)

5.12.5 Emergent BioSolutions Inc Recent Developments

5.13 Novavax, Inc

5.13.1 Novavax, Inc Profile

5.13.2 Novavax, Inc Main Business

5.13.3 Novavax, Inc Recombinant Vaccines Products, Services and Solutions

5.13.4 Novavax, Inc Recombinant Vaccines Revenue (US$ Million) & (2018-2023)

5.13.5 Novavax, Inc Recent Developments

5.14 Serum Institute of India Pvt. Ltd

5.14.1 Serum Institute of India Pvt. Ltd Profile

5.14.2 Serum Institute of India Pvt. Ltd Main Business

5.14.3 Serum Institute of India Pvt. Ltd Recombinant Vaccines Products, Services and Solutions

5.14.4 Serum Institute of India Pvt. Ltd Recombinant Vaccines Revenue (US$ Million) & (2018-2023)

5.14.5 Serum Institute of India Pvt. Ltd Recent Developments

5.15 Dynavax Technologies Corporation

5.15.1 Dynavax Technologies Corporation Profile

5.15.2 Dynavax Technologies Corporation Main Business

5.15.3 Dynavax Technologies Corporation Recombinant Vaccines Products, Services and Solutions

5.15.4 Dynavax Technologies Corporation Recombinant Vaccines Revenue (US$ Million) & (2018-2023)

5.15.5 Dynavax Technologies Corporation Recent Developments

6 North America

6.1 North America Recombinant Vaccines Market Size by Country (2018-2029)

6.2 U.S.

6.3 Canada

7 Europe

7.1 Europe Recombinant Vaccines Market Size by Country (2018-2029)

7.2 Germany

7.3 France

7.4 U.K.

7.5 Italy

7.6 Russia

7.7 Nordic Countries

7.8 Rest of Europe

8 Asia-Pacific

8.1 Asia-Pacific Recombinant Vaccines Market Size by Region (2018-2029)

8.2 China

8.3 Japan

8.4 South Korea

8.5 Southeast Asia

8.6 India

8.7 Australia

8.8 Rest of Asia-Pacific

9 Latin America

9.1 Latin America Recombinant Vaccines Market Size by Country (2018-2029)

9.2 Mexico

9.3 Brazil

9.4 Rest of Latin America

10 Middle East & Africa

10.1 Middle East & Africa Recombinant Vaccines Market Size by Country (2018-2029)

10.2 Turkey

10.3 Saudi Arabia

10.4 UAE

10.5 Rest of Middle East & Africa

11 Recombinant Vaccines Market Dynamics

11.1 Recombinant Vaccines Industry Trends

11.2 Recombinant Vaccines Market Drivers

11.3 Recombinant Vaccines Market Challenges

11.4 Recombinant Vaccines Market Restraints

12 Research Finding /Conclusion

13 Methodology and Data Source

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

13.4 Author List

FEATURED COMPANIES

Merck& Co. Inc

Green Cross Corporation

Pfizer Inc

Bayer

Sanofi

Protein Science Corporation

Emergent BioSolutions Inc

Novavax Inc

Serum Institute of India Pvt. Ltd

Dynavax Technologies Corporation

List of Tables

Table 1. Global Market Recombinant Vaccines Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029

Table 2. Global Recombinant Vaccines Market Size by Region (2018-2023) & (US$ Million)

Table 3. Global Recombinant Vaccines Market Size Share by Region (2018-2023)

Table 4. Global Recombinant Vaccines Forecasted Market Size by Region (2024-2029) & (US$ Million)

Table 5. Global Recombinant Vaccines Forecasted Market Size Share by Region (2024-2029)

Table 6. Global Recombinant Vaccines Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029

Table 7. Global Recombinant Vaccines Market Size by Type (2018-2023) & (US$ Million)

Table 8. Global Recombinant Vaccines Revenue Market Share by Type (2018-2023)

Table 9. Global Recombinant Vaccines Forecasted Market Size by Type (2024-2029) & (US$ Million)

Table 10. Global Recombinant Vaccines Revenue Market Share by Type (2024-2029)

Table 11. North America Recombinant Vaccines Revenue by Type (2018-2023) & (US$ Million)

Table 12. North America Recombinant Vaccines Revenue by Type (2024-2029) & (US$ Million)

Table 13. Europe Recombinant Vaccines Revenue by Type (2018-2023) & (US$ Million)

Table 14. Europe Recombinant Vaccines Revenue by Type (2024-2029) & (US$ Million)

Table 15. Asia-Pacific Recombinant Vaccines Revenue by Type (2018-2023) & (US$ Million)

Table 16. Asia-Pacific Recombinant Vaccines Revenue by Type (2024-2029) & (US$ Million)

Table 17. Latin America Recombinant Vaccines Revenue by Type (2018-2023) & (US$ Million)

Table 18. Latin America Recombinant Vaccines Revenue by Type (2024-2029) & (US$ Million)

Table 19. Middle East and Africa Recombinant Vaccines Revenue by Type (2018-2023) & (US$ Million)

Table 20. Middle East and Africa Recombinant Vaccines Revenue by Type (2024-2029) & (US$ Million)

Table 21. Global Recombinant Vaccines Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029

Table 22. Global Recombinant Vaccines Market Size by Application (2018-2023) & (US$ Million)

Table 23. Global Recombinant Vaccines Revenue Market Share by Application (2018-2023)

Table 24. Global Recombinant Vaccines Forecasted Market Size by Application (2024-2029) & (US$ Million)

Table 25. Global Recombinant Vaccines Revenue Market Share by Application (2024-2029)

Table 26. North America Recombinant Vaccines Revenue by Application (2018-2023) & (US$ Million)

Table 27. North America Recombinant Vaccines Revenue by Application (2024-2029) & (US$ Million)

Table 28. Europe Recombinant Vaccines Revenue by Application (2018-2023) & (US$ Million)

Table 29. Europe Recombinant Vaccines Revenue by Application (2024-2029) & (US$ Million)

Table 30. Asia-Pacific Recombinant Vaccines Revenue by Application (2018-2023) & (US$ Million)

Table 31. Asia-Pacific Recombinant Vaccines Revenue by Application (2024-2029) & (US$ Million)

Table 32. Latin America Recombinant Vaccines Revenue by Application (2018-2023) & (US$ Million)

Table 33. Latin America Recombinant Vaccines Revenue by Application (2024-2029) & (US$ Million)

Table 34. Middle East and Africa Recombinant Vaccines Revenue by Application (2018-2023) & (US$ Million)

Table 35. Middle East and Africa Recombinant Vaccines Revenue by Application (2024-2029) & (US$ Million)

Table 36. Global Recombinant Vaccines Revenue (US$ Million) by Players (2018-2023)

Table 37. Global Recombinant Vaccines Revenue Market Share by Players (2018-2023)

Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Recombinant Vaccines as of 2022)

Table 39. Date of Key Players Enter into Recombinant Vaccines Market

Table 40. Global Recombinant Vaccines Key Players Headquarters and Area Served

Table 41. Recombinant Vaccines Product Solution and Service

Table 42. Global Recombinant Vaccines Players Market Concentration Ratio (CR5 and HHI)

Table 43. Mergers & Acquisitions, Expansion Plans

Table 44. Merck & Co., Inc Basic Information List

Table 45. Merck & Co., Inc Description and Business Overview

Table 46. Merck & Co., Inc Recombinant Vaccines Products, Services and Solutions

Table 47. Revenue (US$ Million) in Recombinant Vaccines Business of Merck & Co., Inc (2018-2023)

Table 48. Merck & Co., Inc Recent Developments

Table 49. Green Cross Corporation Basic Information List

Table 50. Green Cross Corporation Description and Business Overview

Table 51. Green Cross Corporation Recombinant Vaccines Products, Services and Solutions

Table 52. Revenue (US$ Million) in Recombinant Vaccines Business of Green Cross Corporation (2018-2023)

Table 53. Green Cross Corporation Recent Developments

Table 54. Pfizer Inc. Basic Information List

Table 55. Pfizer Inc. Description and Business Overview

Table 56. Pfizer Inc. Recombinant Vaccines Products, Services and Solutions

Table 57. Revenue (US$ Million) in Recombinant Vaccines Business of Pfizer Inc. (2018-2023)

Table 58. Pfizer Inc. Recent Developments

Table 59. Bayer AG Basic Information List

Table 60. Bayer AG Description and Business Overview

Table 61. Bayer AG Recombinant Vaccines Products, Services and Solutions

Table 62. Revenue (US$ Million) in Recombinant Vaccines Business of Bayer AG (2018-2023)

Table 63. Bayer AG Recent Developments

Table 64. Sanofi S A. Basic Information List

Table 65. Sanofi S A. Description and Business Overview

Table 66. Sanofi S A. Recombinant Vaccines Products, Services and Solutions

Table 67. Revenue (US$ Million) in Recombinant Vaccines Business of Sanofi S A. (2018-2023)

Table 68. Sanofi S A. Recent Developments

Table 69. Protein Science Corporation Basic Information List

Table 70. Protein Science Corporation Description and Business Overview

Table 71. Protein Science Corporation Recombinant Vaccines Products, Services and Solutions

Table 72. Revenue (US$ Million) in Recombinant Vaccines Business of Protein Science Corporation (2018-2023)

Table 73. Protein Science Corporation Recent Developments

Table 74. GlaxoSmithKline Plc. Basic Information List

Table 75. GlaxoSmithKline Plc. Description and Business Overview

Table 76. GlaxoSmithKline Plc. Recombinant Vaccines Products, Services and Solutions

Table 77. Revenue (US$ Million) in Recombinant Vaccines Business of GlaxoSmithKline Plc. (2018-2023)

Table 78. GlaxoSmithKline Plc. Recent Developments

Table 79. Novartis AG Basic Information List

Table 80. Novartis AG Description and Business Overview

Table 81. Novartis AG Recombinant Vaccines Products, Services and Solutions

Table 82. Revenue (US$ Million) in Recombinant Vaccines Business of Novartis AG (2018-2023)

Table 83. Novartis AG Recent Developments

Table 84. Bharat Biotech Basic Information List

Table 85. Bharat Biotech Description and Business Overview

Table 86. Bharat Biotech Recombinant Vaccines Products, Services and Solutions

Table 87. Revenue (US$ Million) in Recombinant Vaccines Business of Bharat Biotech (2018-2023)

Table 88. Bharat Biotech Recent Developments

Table 89. AstraZeneca Plc. Basic Information List

Table 90. AstraZeneca Plc. Description and Business Overview

Table 91. AstraZeneca Plc. Recombinant Vaccines Products, Services and Solutions

Table 92. Revenue (US$ Million) in Recombinant Vaccines Business of AstraZeneca Plc. (2018-2023)

Table 93. AstraZeneca Plc. Recent Developments

Table 94. Johnson & Johnson Basic Information List

Table 95. Johnson & Johnson Description and Business Overview

Table 96. Johnson & Johnson Recombinant Vaccines Products, Services and Solutions

Table 97. Revenue (US$ Million) in Recombinant Vaccines Business of Johnson & Johnson (2018-2023)

Table 98. Johnson & Johnson Recent Developments

Table 99. Emergent BioSolutions Inc Basic Information List

Table 100. Emergent BioSolutions Inc Description and Business Overview

Table 101. Emergent BioSolutions Inc Recombinant Vaccines Products, Services and Solutions

Table 102. Revenue (US$ Million) in Recombinant Vaccines Business of Emergent BioSolutions Inc (2018-2023)

Table 103. Emergent BioSolutions Inc Recent Developments

Table 104. Novavax, Inc Basic Information List

Table 105. Novavax, Inc Description and Business Overview

Table 106. Novavax, Inc Recombinant Vaccines Products, Services and Solutions

Table 107. Revenue (US$ Million) in Recombinant Vaccines Business of Novavax, Inc (2018-2023)

Table 108. Novavax, Inc Recent Developments

Table 109. Serum Institute of India Pvt. Ltd Basic Information List

Table 110. Serum Institute of India Pvt. Ltd Description and Business Overview

Table 111. Serum Institute of India Pvt. Ltd Recombinant Vaccines Products, Services and Solutions

Table 112. Revenue (US$ Million) in Recombinant Vaccines Business of Serum Institute of India Pvt. Ltd (2018-2023)

Table 113. Serum Institute of India Pvt. Ltd Recent Developments

Table 114. Dynavax Technologies Corporation Basic Information List

Table 115. Dynavax Technologies Corporation Description and Business Overview

Table 116. Dynavax Technologies Corporation Recombinant Vaccines Products, Services and Solutions

Table 117. Revenue (US$ Million) in Recombinant Vaccines Business of Dynavax Technologies Corporation (2018-2023)

Table 118. Dynavax Technologies Corporation Recent Developments

Table 119. North America Recombinant Vaccines Market Size by Country (2018-2023) & (US$ Million)

Table 120. North America Recombinant Vaccines Market Size by Country (2024-2029) & (US$ Million)

Table 121. Europe Recombinant Vaccines Market Size by Country (2018-2023) & (US$ Million)

Table 122. Europe Recombinant Vaccines Market Size by Country (2024-2029) & (US$ Million)

Table 123. Asia-Pacific Recombinant Vaccines Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 124. Asia-Pacific Recombinant Vaccines Market Size by Region (2018-2023) & (US$ Million)

Table 125. Asia-Pacific Recombinant Vaccines Market Size by Region (2024-2029) & (US$ Million)

Table 126. Asia-Pacific Recombinant Vaccines Market Share by Region (2018-2023)

Table 127. Asia-Pacific Recombinant Vaccines Market Share by Region (2024-2029)

Table 128. Latin America Recombinant Vaccines Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 129. Latin America Recombinant Vaccines Market Size by Country (2018-2023) & (US$ Million)

Table 130. Latin America Recombinant Vaccines Market Size by Country (2024-2029) & (US$ Million)

Table 131. Middle East & Africa Recombinant Vaccines Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 132. Middle East & Africa Recombinant Vaccines Market Size by Country (2018-2023) & (US$ Million)

Table 133. Middle East & Africa Recombinant Vaccines Market Size by Country (2024-2029) & (US$ Million)

Table 134. Recombinant Vaccines Market Trends

Table 135. Recombinant Vaccines Market Drivers

Table 136. Recombinant Vaccines Market Challenges

Table 137. Recombinant Vaccines Market Restraints

Table 138. Research Programs/Design for This Report

Table 139. Key Data Information from Secondary Sources

Table 140. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Recombinant Vaccines Market Size Year-over-Year 2018-2029 & (US$ Million)

Figure 2. Global Recombinant Vaccines Market Size (US$ Million), 2018 VS 2022 VS 2029

Figure 3. Global Recombinant Vaccines Market Share by Regions: 2022 VS 2029

Figure 4. Global Recombinant Vaccines Forecasted Market Size Share by Region (2024-2029)

Figure 5. North America Recombinant Vaccines Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 6. Europe Recombinant Vaccines Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 7. Asia-Pacific Recombinant Vaccines Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 8. Latin America Recombinant Vaccines Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 9. Middle East & Africa Recombinant Vaccines Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 10. Product Picture of Subunit Recombinant Vaccines

Figure 11. Global Subunit Recombinant Vaccines Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 12. Product Picture of Attenuated Recombinant Vaccines

Figure 13. Global Attenuated Recombinant Vaccines Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 14. Product Picture of Vector Recombinant Vaccines

Figure 15. Global Vector Recombinant Vaccines Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 16. Global Recombinant Vaccines Market Size Share by Type: 2022 & 2029

Figure 17. North America Recombinant Vaccines Revenue Market Share by Type (2018-2029)

Figure 18. Europe Recombinant Vaccines Revenue Market Share by Type (2018-2029)

Figure 19. Asia-Pacific Recombinant Vaccines Revenue Market Share by Type (2018-2029)

Figure 20. Latin America Recombinant Vaccines Revenue Market Share by Type (2018-2029)

Figure 21. Middle East and Africa Recombinant Vaccines Revenue Market Share by Type (2018-2029)

Figure 22. Recombinant Human Vaccines Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 23. Animal Recombinant Vaccines Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 24. Global Recombinant Vaccines Market Size Share by Application: 2022 & 2029

Figure 25. North America Recombinant Vaccines Revenue Market Share by Application (2018-2029)

Figure 26. Europe Recombinant Vaccines Revenue Market Share by Application (2018-2029)

Figure 27. Asia-Pacific Recombinant Vaccines Revenue Market Share by Application (2018-2029)

Figure 28. Latin America Recombinant Vaccines Revenue Market Share by Application (2018-2029)

Figure 29. Middle East and Africa Recombinant Vaccines Revenue Market Share by Application (2018-2029)

Figure 30. Recombinant Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022

Figure 31. Global Top 5 and Top 10 Players Recombinant Vaccines Market Share in 2022

Figure 32. North America Recombinant Vaccines Market Share by Country (2018-2029)

Figure 33. U.S. Recombinant Vaccines Market Size (2018-2029) & (US$ Million)

Figure 34. Canada Recombinant Vaccines Market Size (2018-2029) & (US$ Million)

Figure 35. Germany Recombinant Vaccines Market Size (2018-2029) & (US$ Million)

Figure 36. France Recombinant Vaccines Market Size (2018-2029) & (US$ Million)

Figure 37. U.K. Recombinant Vaccines Market Size (2018-2029) & (US$ Million)

Figure 38. Italy Recombinant Vaccines Market Size (2018-2029) & (US$ Million)

Figure 39. Russia Recombinant Vaccines Market Size (2018-2029) & (US$ Million)

Figure 40. Nordic Countries Recombinant Vaccines Market Size (2018-2029) & (US$ Million)

Figure 41. Asia-Pacific Recombinant Vaccines Market Share by Region (2018-2029)

Figure 42. China Recombinant Vaccines Market Size (2018-2029) & (US$ Million)

Figure 43. Japan Recombinant Vaccines Market Size (2018-2029) & (US$ Million)

Figure 44. South Korea Recombinant Vaccines Market Size (2018-2029) & (US$ Million)

Figure 45. Southeast Asia Recombinant Vaccines Market Size (2018-2029) & (US$ Million)

Figure 46. India Recombinant Vaccines Market Size (2018-2029) & (US$ Million)

Figure 47. Australia Recombinant Vaccines Market Size (2018-2029) & (US$ Million)

Figure 48. Latin America Recombinant Vaccines Market Share by Country (2018-2029)

Figure 49. Mexico Recombinant Vaccines Market Size (2018-2029) & (US$ Million)

Figure 50. Brazil Recombinant Vaccines Market Size (2018-2029) & (US$ Million)

Figure 51. Middle East & Africa Recombinant Vaccines Market Share by Country (2018-2029)

Figure 52. Turkey Recombinant Vaccines Market Size (2018-2029) & (US$ Million)

Figure 53. Saudi Arabia Recombinant Vaccines Market Size (2018-2029) & (US$ Million)

Figure 54. UAE Recombinant Vaccines Market Size (2018-2029) & (US$ Million)

Figure 55. Bottom-up and Top-down Approaches for This Report

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3350

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5025

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$6700

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions